The DOI matches its Crossref record; 197 of the 197 references it cites were found in a registry or an index.
Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy
Abstract
Vascular endothelial growth factor A (VEGF-A), the founding member of the vascular permeability factor (VPF)/VEGF family of proteins, is an important angiogenic cytokine with critical roles in tumor angiogenesis. This article reviews the literature with regard to VEGF-A’s multiple functions, the mechanisms by which it induces angiogenesis, and its current and projected roles in clinical oncology. VEGF-A is a multifunctional cytokine that is widely expressed by tumor cells and that acts through receptors (VEGFR-1, VEGFR-2, and neuropilin) that are expressed on vascular endothelium and on some other cells. It increases microvascular permeability, induces endothelial cell migration and division, reprograms gene expression, promotes endothelial cell survival, prevents senescence, and induces angiogenesis. Recently, VEGF-A has also been shown to induce lymphangiogenesis. Measurements of circulating levels of VEGF-A may have value in estimating prognosis, and VEGF-A and its receptors are potential targets for therapy. Recognized as the single most important angiogenic cytokine, VEGF-A has a central role in tumor biology and will likely have an important role in future approaches designed to evaluate patient prognosis. It may also become an important target for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Self-citationAbnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972
Self-citationFailure of blood-island formation and vasculogenesis in Flk-1-deficient mice
Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X.-F., Breitman, M. L., & Schuh, A. C. (1995) · Nature · doi:10.1038/376062a0 · Cited by 3,931
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. J., & Moore, M. W. (1996) · Nature · doi:10.1038/380439a0 · Cited by 3,628
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
O'Reilly, M. (1994) · Cell · doi:10.1016/0092-8674(94)90200-3 · Cited by 3,345
Cited by
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
“Furthermore, as previously noted, VEGF increases vascular permeability and this property underlies important roles of this molecule in inflammation and in other pathological condition”
BackgroundCombination therapy in combating cancer
Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16723 · Cited by 2,543
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
Evolving functions of endothelial cells in inflammation
Pober, J. S., & Sessa, W. C. (2007) · Nature Reviews Immunology · doi:10.1038/nri2171 · Cited by 2,022
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Vascular Endothelial Growth Factor and Angiogenesis
Hoeben, A., Landuyt, B., Highley, M. S., Wildiers, H., Van Oosterom, A. T., & De Bruijn, E. A. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.4.3 · Cited by 1,824
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Signaling Mechanisms Regulating Endothelial Permeability
Mehta, D., & Malik, A. B. (2006) · Physiological Reviews · doi:10.1152/physrev.00012.2005 · Cited by 1,720
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Nishida, N., Yano, H., Nishida, T., Kamura, T., & Kojiro, M. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.3.213 · Cited by 1,434
Jain, R. K., di Tomaso, E., Duda, D. G., Loeffler, J. S., Sorensen, A. G., & Batchelor, T. T. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2175 · Cited by 1,405
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
Winkler, F., Kozin, S. V., Tong, R. T., Chae, S.-S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.011 · Cited by 1,170
Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis
Shibuya, M., & Claesson-Welsh, L. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.11.012 · Cited by 1,062
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039
Holmes, K., Roberts, O. L., Thomas, A. M., & Cross, M. J. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.05.013 · Cited by 1,020
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
Ferrara, N., Hillan, K. J., & Novotny, W. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.132 · Cited by 977
Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Ou, S.-S., Archer, L., Atkins, J. N., Picus, J., Czaykowski, P., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.9847 · Cited by 899
Burger, R. A., Sill, M. W., Monk, B. J., Greer, B. E., & Sorosky, J. I. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5345 · Cited by 882
Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future
Arvizo, R. R., Bhattacharyya, S., Kudgus, R. A., Giri, K., Bhattacharya, R., & Mukherjee, P. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15355f · Cited by 866
The role of hypoxia-inducible factors in tumorigenesis
Rankin, E. B., & Giaccia, A. J. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.21 · Cited by 806
Shibuya, M. (2013) · Journal of Biochemistry · doi:10.1093/jb/mvs136 · Cited by 792
Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Archer, L., Atkins, J. N., Picus, J., Czaykowski, P., Dutcher, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5561 · Cited by 787
VEGFs and receptors involved in angiogenesis versus lymphangiogenesis
Lohela, M., Bry, M., Tammela, T., & Alitalo, K. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.012 · Cited by 738
Wiig, H., & Swartz, M. A. (2012) · Physiological Reviews · doi:10.1152/physrev.00037.2011 · Cited by 722
Lee, S., Jilani, S. M., Nikolova, G. V., Carpizo, D., & Iruela-Arispe, M. L. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200409115 · Cited by 703
Jung, Y.-J., Isaacs, J. S., Lee, S., Trepel, J., & Neckers, L. (2003) · The FASEB Journal · doi:10.1096/fj.03-0329fje · Cited by 679
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Ramjiawan, R. R., Griffioen, A. W., & Duda, D. G. (2017) · Angiogenesis · doi:10.1007/s10456-017-9552-y · Cited by 672
Differential Roles of Vascular Endothelial Growth Factor Receptor-1 and Receptor-2 in Angiogenesis
Shibuya, M. (2006) · BMB Reports · doi:10.5483/bmbrep.2006.39.5.469 · Cited by 623
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Yi, M., Jiao, D., Qin, S., Chu, Q., Wu, K., & Li, A. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0974-6 · Cited by 608
Tumors: Wounds That Do Not Heal—Redux
Dvorak, H. F. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0209 · Cited by 592
Self-citationTumor microenvironment abnormalities: Causes, consequences, and strategies to normalize
Fukumura, D., & Jain, R. K. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21187 · Cited by 584
Biomarkers of response and resistance to antiangiogenic therapy
Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.63 · Cited by 572
Expression and Function of Laminins in the Embryonic and Mature Vasculature
Hallmann, R., Horn, N., Selg, M., Wendler, O., Pausch, F., & Sorokin, L. M. (2005) · Physiological Reviews · doi:10.1152/physrev.00014.2004 · Cited by 574
HCC and angiogenesis: possible targets and future directions
Zhu, A. X., Duda, D. G., Sahani, D. V., & Jain, R. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.30 · Cited by 564
Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor
Zhao, Y., & Adjei, A. A. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0465 · Cited by 558
Therapeutic and diagnostic applications of dendrimers for cancer treatment☆
WOLINSKY, J., & GRINSTAFF, M. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.02.012 · Cited by 540
Kumar, R., Knick, V. B., Rudolph, S. K., Johnson, J. H., Crosby, R. M., Crouthamel, M.-C., Hopper, T. M., Miller, C. G., Harrington, L. E., Onori, J. A., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0193 · Cited by 517
The role of vascular endothelial growth factor (VEGF) in renal pathophysiology
Schrijvers, B. F., Flyvbjerg, A., & De Vriese, A. S. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00621.x · Cited by 504
Pericytes and vascular stability
VONTELL, D., ARMULIK, A., & BETSHOLTZ, C. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.10.019 · Cited by 502
VEGF-A and the Induction of Pathological Angiogenesis
Nagy, J. A., Dvorak, A. M., & Dvorak, H. F. (2007) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.2.010506.134925 · Cited by 474
Self-citationPathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin
Phung, T. L., Ziv, K., Dabydeen, D., Eyiah-Mensah, G., Riveros, M., Perruzzi, C., Sun, J., Monahan-Earley, R. A., Shiojima, I., Nagy, J. A., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.07.003 · Cited by 438
Self-citationRini, B. I., & Small, E. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.186 · Cited by 408
Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
Haibe, Y., Kreidieh, M., El Hajj, H., Khalifeh, I., Mukherji, D., Temraz, S., & Shamseddine, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00221 · Cited by 396
Sorensen, A. G., Batchelor, T. T., Zhang, W.-T., Chen, P.-J., Yeo, P., Wang, M., Jennings, D., Wen, P. Y., Lahdenranta, J., Ancukiewicz, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0814 · Cited by 394
Understanding the biology of angiogenesis: Review of the most important molecular mechanisms
Otrock, Z. K., Mahfouz, R. A. R., Makarem, J. A., & Shamseddine, A. I. (2007) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2007.04.001 · Cited by 386
Targeting RTK Signaling Pathways in Cancer
Regad, T. (2015) · Cancers · doi:10.3390/cancers7030860 · Cited by 380
Vascular endothelial growth factor family of ligands and receptors: Review
Otrock, Z. K., Makarem, J. A., & Shamseddine, A. I. (2007) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2006.12.003 · Cited by 376
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment
Ma, J., & Waxman, D. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0715 · Cited by 370
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
Grothey, A., & Galanis, E. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.110 · Cited by 356
An overview of small-molecule inhibitors of VEGFR signaling
Ivy, S. P., Wick, J. Y., & Kaufman, B. M. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.130 · Cited by 350
Shen, Y., Wang, X., Lu, J., Salfenmoser, M., Wirsik, N. M., Schleussner, N., Imle, A., Freire Valls, A., Radhakrishnan, P., Liang, J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.05.005 · Cited by 339
Targeting the tumor vasculature to enhance T cell activity
Lanitis, E., Irving, M., & Coukos, G. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.011 · Cited by 338
IGF2: Epigenetic regulation and role in development and disease
Chao, W., & D’Amore, P. A. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.01.005 · Cited by 336
Glioblastoma multiforme: State of the art and future therapeutics
Harter, D., Wilson, T., & Karajannis, M. (2014) · Surgical Neurology International · doi:10.4103/2152-7806.132138 · Cited by 327
Kamoun, W. S., Ley, C. D., Farrar, C. T., Duyverman, A. M., Lahdenranta, J., Lacorre, D. A., Batchelor, T. T., di Tomaso, E., Duda, D. G., Munn, L. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9356 · Cited by 309
TESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN)
MANZANO, R. P. A., PEYMAN, G. A., KHAN, P., & KIVILCIM, M. (2006) · Retina · doi:10.1097/00006982-200603000-00001 · Cited by 305
Current approaches to the treatment of metastatic brain tumours
Owonikoko, T. K., Arbiser, J., Zelnak, A., Shu, H.-K. G., Shim, H., Robin, A. M., Kalkanis, S. N., Whitsett, T. G., Salhia, B., Tran, N. L., et al. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.25 · Cited by 304
Oxidative Stress, Gene Expression, and Protein Changes Induced in the Human Placenta during Labor
Cindrova-Davies, T., Yung, H.-W., Johns, J., Spasic-Boskovic, O., Korolchuk, S., Jauniaux, E., Burton, G. J., & Charnock-Jones, D. S. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070528 · Cited by 297
DVORAK, H. F. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01361.x · Cited by 296
Self-citationThe renin-angiotensin system and malignancy
Ager, E. I., Neo, J., & Christophi, C. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn171 · Cited by 295
(1926) · The American Journal of Surgery · doi:10.1016/s0002-9610(26)90068-8 · Cited by 293
Polverino, A., Coxon, A., Starnes, C., Diaz, Z., DeMelfi, T., Wang, L., Bready, J., Estrada, J., Cattley, R., Kaufman, S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4665 · Cited by 287
Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis
Shibuya, M. (2008) · BMB Reports · doi:10.5483/bmbrep.2008.41.4.278 · Cited by 277
Morabito, A., De Maio, E., Di Maio, M., Normanno, N., & Perrone, F. (2006) · The Oncologist · doi:10.1634/theoncologist.11-7-753 · Cited by 274
The role of neuropilins in cancer
Ellis, L. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0538 · Cited by 263
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
He, Y., Xu, W., Xiao, Y.-T., Huang, H., Gu, D., & Ren, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01042-7 · Cited by 261
Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy
Ellis, L. M., & Hicklin, D. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5287 · Cited by 257
Age‐related changes in Drosophila midgut are associated with PVF2, a PDGF/VEGF‐like growth factor
Choi, N., Kim, J., Yang, D., Kim, Y., & Yoo, M. (2008) · Aging Cell · doi:10.1111/j.1474-9726.2008.00380.x · Cited by 260
Contribution of adipose tissue to development of cancer
Cozzo, A. J., Fuller, A. M., & Makowski, L. (2017) · Comprehensive Physiology · doi:10.1002/cphy.c170008 · Cited by 188
Choi, Y., & Jung, K. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01114-w · Cited by 188
Kodack, D. P., Chung, E., Yamashita, H., Incio, J., Duyverman, A. M. M. J., Song, Y., Farrar, C. T., Huang, Y., Ager, E., Kamoun, W., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216078109 · Cited by 153
“VEGF is one of the most potent angiogenic factors (14).”
BackgroundSuehara, Y., Alex, D., Bowman, A., Middha, S., Zehir, A., Chakravarty, D., Wang, L., Jour, G., Nafa, K., Hayashi, T., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4032 · Cited by 135
Steel, J. L., Geller, D. A., Kim, K. H., Butterfield, L. H., Spring, M., Grady, J., Sun, W., Marsh, W., Antoni, M., Dew, M. A., et al. (2016) · Cancer · doi:10.1002/cncr.29906 · Cited by 116
Hossein Pourgholami, M., Yan Cai, Z., Lu, Y., Wang, L., & Lawson Morris, D. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1181 · Cited by 100
Current targeted therapies in the treatment of advanced colorectal cancer: a review
Moriarity, A., O’Sullivan, J., Kennedy, J., Mehigan, B., & McCormick, P. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016646734 · Cited by 87
Urinary vitamin D-binding protein is elevated in patients with endometriosis
Cho, S., Choi, Y. S., Yim, S. Y., Yang, H. I., Jeon, Y. E., Lee, K. E., Kim, H., Seo, S. K., & Lee, B. S. (2012) · Human Reproduction · doi:10.1093/humrep/der345 · Cited by 74
Evaluation of Serum and Urinary Angiogenic Factors in Patients with Endometriosis
Cho, S. H., Oh, Y. J., Nam, A., Kim, H. Y., Park, J. H., Kim, J. H., Park, K. H., Cho, D. J., & Lee, B. S. (2007) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2007.00535.x · Cited by 68
Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data
Hansen, T. F., Qvortrup, C., & Pfeiffer, P. (2021) · Cancers · doi:10.3390/cancers13051031 · Cited by 43
Gene expression profiling analysis of osteosarcoma cell lines
SUN, L., LI, J., & YAN, B. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3958 · Cited by 27
Metadata
- Authors
- Dvorak, H. F.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-11-01
- Volume
- 20
- Issue
- 21
- Pages
- 4368-4380
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2076424556
- Cited by
- 1,573
- References
- 197
- FWCI
- 18.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.